Cephalon's Provigil Produces Eye-Opening 40% Off-label Use - CEO Baldino

11 Oct 1999

• By The Pink Sheet

About 40% of scripts for Cephalon's narcolepsy therapy Provigil (modafinil) are being written for off-label indications, Cephalon CEO Frank Baldino said at a Burns McClellan/Petkevich & Partners analyst meeting in London Oct. 6.

Cephalon's Provigil Produces Eye-Opening 40% Off-label Use - CEO Baldino

More from Archive

More from Pink Sheet